Calls
2
Eric Tse
CEO, Sino Biopharmaceuticals
Win Rate
50.0%
return
-7.9%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 23
$6.55
-16.5%
Sino Biopharmaceuticals will stay focused on oncology, hepatitis, surgery, and respiratory areas while exploring cardiovascular and metabolism. It has good molecules attracting big pharma interest and expects M&A, licensing, and partnership opportunities to drive growth.
Other
Long
Jan 23
$18.18
+0.7%
China's clinical trial registrations have surged from about 5% to one third of global trials, helped by government innovation support, population scale, and cost efficiency. M&A and licensing deal value has reached roughly $100 billion, creating a large opportunity set.
Equity Indexes
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Eric Tse has 2 trade ideas tracked on Buzzberg across 2 tickers since January 2026. Most covered: KURE, 1177.HK.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
